|
|
Dendreon News (NASDAQ:DNDN)
| Latest Dendreon News Headlines | | Date | Time | Source | | | 11/07/2008 | 7:30AM | PRNUS | Dendreon Reports Third Quarter 2008 Financial Results
SEATTLE, Nov. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today reported results for the quarter ended September 30, 2008. Revenue for the third quarter of 2008 was $26,000 compared to $112,000 for the quarter ended September 30, 2007. Revenue for the nine months ended September 30, 2008 was $83,000... More...>> |
| 11/06/2008 | 7:30AM | PRNUS | Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
SEATTLE, Nov. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today will present a summary of Phase 1 clinical data of NEUVENGE(TM) (lapuleucel-T), an investigational active cellular immunotherapy, at the Chemotherapy Foundation Symposium in New York City. The presentation, which integrates the data from... More...>> |
| 11/05/2008 | 7:30AM | PRNUS | Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
SEATTLE, Nov. 5 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the following investor conferences in November.
Rodman & Renshaw 10th Annual Healthcare Conference
New York Palace Hotel
Wednesday, November 12, 2008
9:55 a.m. ET
Lazard Capital Markets... More...>> |
| 10/23/2008 | 7:30AM | PRNUS | Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
-- Data Presented at 20th EORTC-NCI-AACR Symposium --
SEATTLE and GENEVA, Oct. 23 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (NASDAQ:DNDN) today presented preclinical data on its lead small molecule candidate, D-3263, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8... More...>> |
| 10/07/2008 | 9:00AM | PRNUS | Beacon Equity Issues Technical Trade Alerts on Market Movers: DNDN, SPSN, SONS, CEGE, IDEV, ARDM
DALLAS, Oct. 7 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m
Today's Trade Alerts include: Dendreon Corp. (NASDAQ:DNDN), Spansion Inc. (NASDAQ:SPSN), Sonus... More...>> |
| 10/06/2008 | 8:30AM | PRNUS | Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
- Conference Call Scheduled for 9:00 AM ET Today -
SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) announced today that it has completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment... More...>> |
| 10/06/2008 | 7:00AM | PRNUS | Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
SEATTLE, Oct. 6 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) will host a conference call today, Monday, October 6, 2008 at 9:00 AM ET (6:00 AM PT) to review the outcome of the interim analysis of its IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of... More...>> |
| 09/17/2008 | 7:30AM | PRNUS | Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
SEATTLE, Sept. 17 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that Mitchell H. Gold, M.D., president and chief executive officer of Dendreon, will present a company update at the UBS Global Life Sciences Conference in New York City, on Monday, September 22, 2008 at 1:30 p.m. ET.
A live... More...>> |
| 08/29/2008 | 7:30AM | PRNUS | Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
SEATTLE, Aug. 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that Greg Schiffman, chief financial officer of Dendreon, will present a company update at the Newsmakers in the Biotech Industry Conference in New York City, on Thursday, September 4, 2008 at 3:55 p.m. ET.
A live audio webcast... More...>> |
| 08/14/2008 | 7:30AM | PRNUS | Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
SEATTLE, Aug. 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that the Company has initiated its second of two new Phase 2 trials of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. The multicenter trial... More...>> |
| 08/13/2008 | 7:00AM | PRNUS | Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
SAN MATEO, Calif., Aug. 13 /PRNewswire/ -- Anthera Pharmaceuticals Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, today announced the completion of a $19 Million equity financing. New investors Caxton Advantage Life Sciences Fund (New York, NY) and HBM BioCapital (Cayman Islands... More...>> |
| 08/12/2008 | 7:30AM | PRNUS | Dendreon Reports Second Quarter 2008 Financial Results
- Management Will Host Conference Call Today at 4:30 p.m. EDT -
SEATTLE, Aug. 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) reported results for the quarter ended June 30, 2008.
Revenue for the second quarter of 2008 was $26,000 compared to $523,000 for the quarter ended June 30, 2007. Revenue for... More...>> |
| 08/07/2008 | 7:30AM | PRNUS | -Dendreon to Hold Conference Call on Tuesday, August 12, 2008 at 4:30 PM ET-
SEATTLE, Aug. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) will hold its second quarter earnings call on Tuesday, August 12, 2008. Company management will host the conference call at 1:30 p.m. PT (4:30 p.m. ET) to review second quarter financial results. Access to the discussion may be obtained as... More...>> |
| 07/23/2008 | 7:30AM | PRNUS | Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
SEATTLE, July 23 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that it expects the Independent Data Monitoring Committee (IDMC) to review in October 2008 the interim analysis of overall survival relating to the Company's Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment... More...>> |
| 07/16/2008 | 7:30AM | PRNUS | Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
SEATTLE, July 16 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that the Company has initiated a Phase 2 trial of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of prostate cancer, in men with localized prostate cancer who are scheduled... More...>> |
| 06/04/2008 | 7:30AM | PRNUS | Dendreon Announces Webcast Presentation at Needham 7th Annual Biotechnology and Medical Technology Conference
SEATTLE, June 4 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that Greg Schiffman, chief financial officer of Dendreon, will present a company update at the Needham 7th Annual Biotechnoloy and Medical Technology Conference in New York City, on Wednesday, June 11, 2008 at 9:30 a.m. ET.
A... More...>> |
| 05/21/2008 | 7:30AM | PRNUS | Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
- Data Presented at American Urological Association Annual Meeting -
SEATTLE and ORLANDO, Fla., May 21 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation (NASDAQ:DNDN) today presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets Trp-p8... More...>> |
| 05/08/2008 | 7:00AM | PRNUS | Dendreon Reports First Quarter 2008 Financial Results
SEATTLE, May 8 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today reported results for the first quarter ended March 31, 2008. Revenue for the first quarter of 2008 was $31,000 compared to $80,000 for the quarter ended March 31, 2007.
Dendreon's total operating expenses for the three months ended March... More...>> |
| 04/30/2008 | 7:30AM | PRNUS | Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
SEATTLE, April 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that management will present at the following investor conferences in May.
Deutsche Bank 33rd Annual Health Care Conference
InterContinental Boston
Tuesday, May 6, 2008
8:50 a.m. ET
Bank of America Health Care... More...>> |
| 04/08/2008 | 6:00PM | PRNUS | Dendreon Announces Closing of Registered Direct Offering
SEATTLE, April 8, 2008 /PRNewswire-FirstCall/ -- Dendreon Corporation (NASDAQ:DNDN) today announced that it has completed the previously announced registered direct offering of 8.0 million shares of its common stock and warrants to purchase up to 8.0 million shares of its common stock. Net proceeds received by Dendreon... More...>> |
|
|
|